Stock PYPD POLYPID LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News PolyPid Ltd.

Equities

PYPD

IL0011326795

Delayed Nasdaq
Other stock markets
 14:56:40 03/05/2024 BST 		5-day change 1st Jan Change
4.94 USD +2.92% Intraday chart for PolyPid Ltd. +3.95% +30.00%
04-30 PolyPid Ltd. Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections CI
02-14 Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections
AQ
PolyPid to Participate in Citizens JMP Life Sciences Conference
AQ
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
AQ
PolyPid Ltd. Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections
CI
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
AQ
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
AQ
Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024
PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
AQ
PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial
CI
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
AQ
PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.
CI
PolyPid Enters Into $16.2 Million Private Placement Deal
MT
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
AQ
PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors
CI
Transcript : PolyPid Ltd., Q3 2023 Earnings Call, Nov 08, 2023
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
AQ
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PYPD Stock
  4. News PolyPid Ltd.